Plus, troubles are brewing among loans favoured by private equity, and venture capital makes a big bet on defence tech
Big companies that sought Chapter 11 to manage settlements will be forced to reconsider strategy after Purdue decision
Members of OxyContin maker’s founding family had fought to uphold protections in $6bn opioid settlement
Some of this is just getting silly
Members of the company’s founding family fight to uphold protections from $6bn opioid bankruptcy settlement in closely watched case
Consultancy admits no wrongdoing as it resolves claims from municipalities and school districts
Justices will consider whether the law permits the waiver of future claims against parties not in bankruptcy
A court ruling clears the way for swift payment for those affected by the US opioid crisis
Appeals court says some liability releases are ‘appropriate’ under US bankruptcy law
Decision comes at end of review instigated by new vice-chancellor Irene Tracey
Documents show privileged access to the Boat Race and continued acceptance of donations
Congressional probe found 22 consultants had advised both the US FDA and drug manufacturers over a decade
Members of Sackler family who owned OxyContin maker will increase financial contribution but still receive a legal shield
Proposal revealed by court mediator comes after a judge rejected earlier deal
It is unfortunate that critics of the current system have not articulated a better one for the aggrieved
Sackler family was to make multibillion-dollar contribution in exchange for protection from lawsuits
Move is the latest fallout for members of the family that owned opioid maker Purdue Pharma
Writer Beth Macy and director Barry Levinson discuss taking on the Sacklers and victim-blaming in their mini-series
Judge approves bankruptcy plan for opioid maker in which family will pay $4.5bn
Critics say concessions in case regarding the company diminishes accountability in overdose scandal
Agreement with holdouts brings US drugmaker a step closer to emerging from bankruptcy
Patrick Radden Keefe’s saga of how a pharmaceutical dynasty unleashed a wave of dependency and grew rich from it
Agreement brings consultancy’s total bill for prescription painkiller advice to $619m
Owners of opioid maker Purdue Pharma pledge extra money to win over US states that rejected deal
Answers emerge as to the unexplained departures from the consultancy’s investment banking research unit